Showing results for pea1 pea2 peo 20152107 20152107 20152107 20152107 20152107 20152107 peo 20152107 20152107 20152107 20152107 20152107 20152107 20152107 20152107 20152107 20152107 20152107

PEO6 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC)

PEO6 Cell Line Product

PEO6 is an adherent cell line derived from a malignant effusion from the peritoneal ascites of a patient with a poorly differentiated serous adenocarcinoma.

PEO4 Cell Line

PEO4 Cell Line Product

The PEO4 cell line is one of nine from the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer, isolated from various malignant sites, and […]

PEO1 Cell Line. 3 days post plating. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC)

PEO1 Cell Line Product

The PEO1 Cell Line is one of nine lines from the PE ovarian adenocarcinoma panel. These lines were derived from 4 patients at varying stages of ovarian cancer and were […]

PEO1 Cell Line. 3 days post plating. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC)

Driving discovery with our cancer cell lines Blog Post

[…] width=”5/6″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][split_line_heading line_reveal_by_space_text_effect=”default” font_style=”h3″ text_color=”#ae78b7″ content_alignment=”default” mobile_content_alignment=”inherit” animation_type=”line-reveal-by-space” link_target=”_self” text_content=” PEO series: tracing drug resistance in ovarian cancer” text_direction=”default”][/split_line_heading][vc_row_inner column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” text_align=”left” row_position=”default” […]

HCI-044 breast cancer PDX Product

HCI-044 PDX – Human breast cancer-derived xenograft retains high fidelity to original tumour. Valuable resources for drug discovery and precision oncology.